Abstracts tagged "Biomarkers and juvenile idiopathic arthritis (JIA)"

Abstract Number: 2312 • 2017 ACR/ARHP Annual Meeting
Prevalence of Serum 14-3-3η (eta) in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Quest Diagnostics Nichols Institute, clemente, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Children’s Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 2327 • 2017 ACR/ARHP Annual Meeting
14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients
Austin M. Dalrymple¹, Paul Tuttle IV¹, Lance Feller², Olga S. Zhukov³, Robert J. Lagier⁴, Robert Bridgforth⁵, Gary J Williams⁵, Joanna M. Popov³, Stanley J. Naides³ and Terry Moore⁶, ¹Division of Adult & Pediatric Rheumatology, Saint Louis University School of Medicine, Saint Louis, MO, ²Rheumatology, Inland Hospital, Waterville, ME, ³Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁴Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁵Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁶Division of Adult & Pediatric Rheumatology, Saint Louis University School of Medicine, St. Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium
Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis
Iris Reyhan¹, Olga S. Zhukov², Robert J. Lagier³, Robert Bridgforth⁴, Gary J Williams⁵, Joanna M. Popov², Stanley J. Naides² and Andreas Reiff⁶, ¹Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, ²Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴quest diagnostics Nichols Institue, clemente, CA, ⁵Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ⁶Childrens Hospital of Los Angeles, Los Angeles, CA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
Abstract Number: 136 • 2017 Pediatric Rheumatology Symposium
14-3-3π(eta) Protein in Juvenile Idiopathic Arthritis
Austin Dalrymple^1,2,3, Paul Tuttle IV⁴, Lance Feller⁵, Olga S. Zhukov⁶, Robert J. Lagier⁷, Robert Bridgforth⁸, Gary J Williams⁹, Joanna Popov¹⁰, Stanley J. Naides⁶ and Terry Moore¹¹, ¹Division of Rheumatology and Pediatric Rheumatology, Saint Louis University School of Medicine, St Louis, MO, ²Division of Adult and Pediatric Rheumatology, Saint Louis University, St Louis, MO, ³Division of Rheumatology and Pediatric Rheumatology, Saint Louis University, St Louis, MO, ⁴Saint Louis University, Saint Louis, MO, ⁵Former fellow, Saint Louis University, Watertown, ME, ⁶Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ⁷Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁸nichols Institute, Quest Diagnostics, San Juan Capistrano, CA, ⁹Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, ¹⁰Immunology, Quest Diagnostics, San Jian Capistrano, CA, ¹¹Rheumatology, Saint Louis University, St. Louis, MO
Background/Purpose: 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…
Abstract Number: 381 • 2016 ACR/ARHP Annual Meeting
Calprotectin As a Multipotent Biomarker in Juvenile Idiopathic Arthritis
Celine La¹, Phu-Quoc Le², Bernard R. Lauwerys³, Laurence Goffin⁴, Alina Ferster⁵, Julie Smet⁶, Patrick Stordeur⁷, Cecile Boulanger⁸, Jean-Pierre Brasseur⁹, Benoit Brasseur¹⁰, David Tuerlincks¹¹, Delphine Spruyt¹², Paschalis Sidiras¹³, Joanne Rasschaert¹², Viviane de Maertelaer¹⁴, Sandra Kleimberg¹⁵, Tatiana Sokolova¹⁶, Patrick Durez^17,18 and Valérie Badot^1,19, ¹Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium, ²Service d'hemato-oncologie, Hopital Universitaire des enfants Reine Fabiola (HUDERF), 1020, Belgium, ³Service de rhumatologie, Pôle de pathologies rhumatismales inflammatoires et systémiques, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁴Service de pédiatrie, Hopital Universitaire des enfants Reine Fabiola (HUDERF), Brussels, Belgium, ⁵Service d'Onco-Hématologie, Hôpital Reine Fabiola, Brussels, Belgium, ⁶Laboratorire d'Immunologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ⁷Laboratoire d'Immunologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ⁸Service d'hématologie et Oncologie pédiatrique, Clinique universitaire Saint-Luc, Brussels, Belgium, ⁹Service de rhumatologie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹⁰Service de Pédiatrie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹¹Service de pédiatrie, Hopital Universitaire Mont-Godinne, Yvoir, Belgium, ¹²Laboratory of Bone and Metabolic Biochemistry, Université Libre de Bruxelles, Brussels, Belgium, ¹³Service de Rhumatologie, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ¹⁴Service de Biostatistique et Informatique Médicale, Université Libre de Bruxelles, Brussels, Belgium, ¹⁵Service de Rhumatologie et de Médecine Physique, Hopital Erasme-Université Libre de Bruxelles, Brussels, Belgium, ¹⁶Project Coordinator, CAP 48 cohort, Brussels, Belgium, ¹⁷Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁸Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹⁹Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: Lack of specific diagnostic, prognostic or response to treatment markers in juvenile idiopathic arthritis (JIA) leads to study new potential markers, as serum calprotectin…
Abstract Number: 932 • 2014 ACR/ARHP Annual Meeting
MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis
Janneke Anink¹, Marieke H. Otten¹, Lisette W.A. van Suijlekom-Smit¹, Marion A.J. Van Rossum², Koert M. Dolman³, Esther P.A. Hoppenreijs⁴, Rebecca ten Cate⁵, Simona Ursu⁶, Lucy R Wedderburn⁷, Gerd Horneff⁸, Thomas Vogl^9,10, Dirk Föll^10,11, Johannes Roth^9,12 and Dirk Holzinger^10,13, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ³Pediatric Rheumatology, St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, ⁴Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁵Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁷Rheumatology Unit, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁸Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁹Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ¹⁰Interdisciplinary Centre for Clinical Research IZKF, University Hospital Muenster, Muenster, Germany, ¹¹Pediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany, ¹²University Hospital Muenster, Muenster, Germany, ¹³Pediatric Rheumatology and Immunology, University Children’s Hospital Muenster, Muenster, Germany
Background/Purpose: Biological therapy has dramatically improved the treatment of patients with JIA. However, there is still a group of patients that shows a lack of…
Abstract Number: 2200 • 2013 ACR/ARHP Annual Meeting
Fatty Acid Profiling In Juvenile Idiopathic Arthritis: The Balance Between Pro-Inflammatory and Pro-Resolving Prostanoids
Weng Tarng Cham¹, Enzo Ranieri², Janice Fletcher² and Christina A. Boros³, ¹Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, ²Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, ³Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia
Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) and are involved in all aspects of…
Abstract Number: 2595 • 2012 ACR/ARHP Annual Meeting
S100A12 At Baseline May Be Useful for Predicting Inactive Disease within 12 Months in Polyarticular Juvenile Idiopathic Arthritis
Gali Malul¹, Joy M. Whitbred¹, MaryAnn O'Riordan², Sarah Ringold³, Susan D. Thompson⁴, Carol Wallace⁵, Salvatore Albani⁶ and Nora G. Singer⁷, ¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²Pediatrics, Case Medical Center, Cleveland, OH, ³Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁴Department of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Div Rheumatology-Pediatrics, Childrens Hosp & Regional Med, Seattle, WA, ⁶Translational Research Program, Infectious and Inflammatory Diseases, Sanford-Burnham Medical Research Institute, La Jolla, CA, ⁷Medicine, Division of Rheumatology, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Achieving clinically inactive disease (ID) is a therapeutic goal in JIA. ID is defined as: no active arthritis; no fever, rash, serositis, splenomegaly or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].